Jane Evenson

Jane Evenson

Jane is a Partner in the highly regarded life sciences team. She joined Mathys & Squire after spending eleven years working in another London private practice. ¬†Prior to that she worked in-house for two large multinational companies.¬†Clients have praised Jane's approach as being ‚Äúproactive‚ÄĚ and for being ‚Äúthe right person for the job‚ÄĚ.

Jane Evenson


Year joined: 2009

Qualifications: BSc EPA CPA


Jane's practice focuses on written and oral representation before the EPO in examination and opposition proceedings at first instance and at appeal. Through careful analysis, creative thinking and skilful advocacy, Jane has an excellent track record in offensive and defensive opposition and in finding solutions for taking EP patent applications to grant where the examiner’s view has become entrenched. She also has considerable expertise in portfolio management and competitor surveillance, opinion work, particularly advising on infringement and validity issues, and due diligence reviews. 

Jane also has a wealth of practical experience in negotiating the various national systems for successfully applying for and prosecuting supplementary protection certificates (SPCs) in Europe. Jane has nearly 20 years' experience working in the life sciences field. She has particular expertise in oligonucleotide, peptide and protein-based technologies including therapeutic and diagnostic antibodies, and antibody conjugates, antisense oligonucleotides, diagnostic assays, PCR and amplification reaction technology, vaccines, fusion proteins, protein biomarkers, cytokines, and transgenic plants and in biofuel technology.


Jane has a degree in chemistry with biotechnology from the University of Durham.




Membership & Organisations

Jane is a member of the CIPA and the EPI.

Sectors & Specialisms

Jane works with clients in the following sectors:
Biotechnology, life sciences

Jane specialises in: 
Patent applications, patent drafting and filing, freedom to operate, due diligence, patent enforcement, IP strategy, patent portfolio management, licensing, patent oppositions, commercialisation

Follow us on twitter